Health - Jun 17
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
wire - news in brief
« BACK
Health - Pharmacology - 17.06.2019
Health - Pharmacology - 14.06.2019
Pharmacology - Health - 14.06.2019
Pharmacology - Health - 12.06.2019
Pharmacology - Health - 12.06.2019
Pharmacology - Health - 11.06.2019
Health - Pharmacology - 10.06.2019
Business / Economics - Pharmacology - 07.06.2019
Pharmacology - Health - 06.06.2019
Health - Pharmacology - 06.06.2019
Pharmacology - Health - 04.06.2019
Pharmacology - Health - 04.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 02.06.2019
Health - Pharmacology - 01.06.2019
Pharmacology - Health - 30.05.2019
Health - Pharmacology - 29.05.2019
Health - Pharmacology - 24.05.2019
Health - Pharmacology - 24.05.2019
Pharmacology - Health - 24.05.2019
Health - Pharmacology - 24.05.2019
Pharmacology - Health - 23.05.2019
Pharmacology - Health - 22.05.2019
Health - Pharmacology - 21.05.2019
Pharmacology - Life Sciences - 21.05.2019 
Treating muscular disease - Santhera and Biozentrum join forces
Santhera Pharmaceuticals and the University of Basel's Biozentrum announce their collaboration to advance gene therapy research for the treatment of congenital muscular dystrophy.
Pharmacology - Health - 16.05.2019
Health - Pharmacology - 16.05.2019
Pharmacology - Health - 16.05.2019
Health - Pharmacology - 14.05.2019
Pharmacology - Health - 10.05.2019
Pharmacology - Health - 10.05.2019
Pharmacology - Health - 09.05.2019
Pharmacology - Business / Economics - 09.05.2019
Pharmacology - Health - 08.05.2019
Pharmacology - Life Sciences - 07.05.2019
Health - Pharmacology - 07.05.2019
Pharmacology - Health - 06.05.2019
Life Sciences - Pharmacology - 05.05.2019
Pharmacology - Health - 02.05.2019
Pharmacology - Life Sciences - 30.04.2019
Pharmacology - Health - 30.04.2019
Pharmacology - Life Sciences - 29.04.2019
Pharmacology - Business / Economics - 24.04.2019
Health - Pharmacology - 23.04.2019
Life Sciences - Pharmacology - 16.04.2019
Pharmacology - Health - 15.04.2019
Pharmacology - Health - 15.04.2019
Pharmacology - 12.04.2019
Pharmacology
Results 1 - 50 of 171.
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar + Mekinist
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from
Data will be presented at the American Society of Clinical Oncology (ASCO) annual meeting on 2 June 2019 Roche today announced positive additional results of a prespecified exploratory analysis from
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973) After a median of 42 months follow-up, the survival rate was 70&pe
Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled
Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled
FDA approves Novartis Piqray - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulve
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulve
AveXis Announces Innovative Zolgensma Gene Therapy Access Programs for US Payers and Families
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD 425,000
One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD 425,000
AveXis receives FDA approval for Zolgensma , the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 , Zolg
SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2 , Zolg
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled c
Bern Center for Precision Medicine inaugurated
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
The Bern Center for Precision Medicine (BCPM) of the University of Bern and Inselspital, University hospital of Bern, were officially opened today in the presence of Director of Education Christine Häsler.
Santhera Pharmaceuticals and the University of Basel's Biozentrum announce their collaboration to advance gene therapy research for the treatment of congenital muscular dystrophy.
Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO Primary results of
Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour types harbouring neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kina
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta off
New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world’s leading cause of infectious disease deaths
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample Roche today announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.
Novartis data at AAN show Gilenya is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in other key measures of disease activity, such as brain lesions There were more discontinuations on glatiramer acetate compared to Gilenya reinforcing Gil
Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duratio
Novartis data at AAN show Mayzent’s positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients Impairment in cognitive function, one of the most disabling aspects of MS, affects 50-70% of patients and is more severe in patients with SPMS EXPAND findings demonstrate that SPMS patients treated earlier in the cou
New AveXis data at AAN showed long-term durability of Zolgensma in patients with spinal muscular atrophy (SMA) Type 1
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolge
Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing with Zolge
Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively Data presented at AAN show that MSProDiscuss TM , a scientifically-validated digital tool, was able to provide information to support differentiation between RRMS and SPMS with high sensitivity and specificity These fin
FDA approves Roche’s Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The
AveXis presented robust data at AAN demonstrating efficacy of Zolgensma in broad spectrum of spinal muscular atrophy (SMA) patients
Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)
Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101)
Novartis to highlight extensive long-term safety and efficacy data of Aimovig across the spectrum of migraine at AAN
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study showed
New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl
Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple scl
New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor milestones and improved survival after one year of treatment New analyses in re
Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.
AveXis data reinforce effectiveness of Zolgensma in treating spinal muscular atrophy (SMA) Type 1
Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human biodist
Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial First-in-human biodist
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER
By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries Filing is based on Phase III data from the HAWK and HARRIER
Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.
The University of Zurich coordinates a worldwide research project that focuses on the development of new biomarkers.
Computational power in the fight against cancer
Vittorio Limongelli, Associate professor at the USI Faculty of Biomedical Sciences and at the USI Institute of Computational Science (ICS), has recently received a competitive research funding consis
Vittorio Limongelli, Associate professor at the USI Faculty of Biomedical Sciences and at the USI Institute of Computational Science (ICS), has recently received a competitive research funding consis
Health - Jun 17
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy